Maisano R, Adamo V, Toscano G, Chiofalo G, Pergolizzi S, Scimone A
Instituto Nazionale per la Ricerca sul Cancro, Sezione di Messina, Italy.
Anticancer Res. 1997 Jul-Aug;17(4A):2775-7.
Vinorelbine is active in a variety of malignancies. The most common side effects are leukopenia and granulocytopenia, moreover Vinorelbine is a vescicant and venous irritant, the incidence of the latter being 10-26% in patients who received VNB as a 20-30 minute peripheral infusion. To prevent venous toxicity we have carried out a study in order to evaluate the efficacy of Defibrotide in this issue.
41 patients were enrolled in the study, the experimental schedule was: Defibrotide 400 mg on 250 cc of normal saline iv, after 15 minutes of infusion, we delivered quick, brief and repeated pulses of Vinorelbine through the plastic tube followed by remaining Defibrotide: For grading venous irritation we used the scale by Rittenberg et al.
A total of 360 infusion were delivered, the incidence of any venous irritation was 5% and maximum grade 2. No severe toxicity was recorded.
These data show that Defibrotide might serve as a therapeutic drug to prevent vascular toxicity by Vinorelbine.
长春瑞滨对多种恶性肿瘤有效。最常见的副作用是白细胞减少和粒细胞减少，此外长春瑞滨是一种发泡剂和静脉刺激剂，在接受20 - 30分钟外周静脉输注长春瑞滨的患者中，后者的发生率为10 - 26%。为预防静脉毒性，我们开展了一项研究以评估去纤苷在该问题上的疗效。
41例患者纳入本研究，实验方案为：将400 mg去纤苷加入250 cc生理盐水中静脉输注，输注15分钟后，通过塑料管快速、短暂且重复推注长春瑞滨，随后输注剩余的去纤苷；对于静脉刺激分级，我们采用Rittenberg等人的量表。
共进行了360次输注，任何静脉刺激的发生率为5%，最高为2级。未记录到严重毒性。
这些数据表明，去纤苷可能作为一种治疗药物来预防长春瑞滨引起的血管毒性。
